InventisBio Announces Positive Phase II Results for D-2570 in Psoriasis Treatment
China-based InventisBio (Shanghai) Co., Ltd (SHA: 688382) announced positive results from the Phase II study...
SHA: 688382
InventisBio’s Oral TYK2 Inhibitor D-2570 Achieves Positive Results in Phase II Psoriasis Study
China-based InventisBio (Shanghai) Co., Ltd (SHA: 688382) has announced the successful completion of a Phase...
InventisBio Acquires Immuno-Oncology Assets from Lyvgen Biopharma in RMB1.5 Million Deal
InventisBio (Shanghai) Co., Ltd (SHA: 688382), a Chinese biotechnology company, has announced a transfer agreement...
InventisBio’s KRAS G12C Inhibitor Garsorasib NDA Accepted for Review by China’s NMPA
InventisBio (Shanghai) Co., Ltd (SHA: 688382), a China-based pharmaceutical company, has announced that the New...
InventisBio’s KRAS G12C Inhibitor D-1553 Advances Toward Priority Review in China
According to the China Center for Drug Evaluation (CDE), Shanghai-based InventisBio Co., Ltd. (SHA: 688382)...
Betta Pharmaceuticals’ MCLA-129 Combo Therapy for NSCLC Gets NMPA Clinical Approval
China-based Betta Pharmaceuticals Co., Ltd (SHE: 300558) has announced that it has received clinical trial...
Betta Pharmaceuticals’ Befotertinib Approved by China’s NMPA for EGFR-Mutated NSCLC
China-based Betta Pharmaceuticals Co., Ltd (SHE: 300558) has announced receiving market approval from the National...
Mirati Therapeutics Sues InventisBio Over Trade Secret Misappropriation
US-based Mirati Therapeutics (Nasdaq: MRTX) is reportedly suing China-based InventisBio Co., Ltd (SHA: 688382) over...
InventisBio Raises USD 308M in Shanghai STAR IPO, Valued at USD 1.54B
China-based biotech firm InventisBio (SHA: 688382) has completed an initial public offering (IPO) of 115...